Category: Merck & Co.

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

TOKYO, Dec 11, 2023 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA®, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA®,…

Continue Reading Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Merck & Co., Inc. Announces Phase 3 Keynote-564 Trial Evaluating KEYTRUDA, Merck?s Anti-PD-1 Therapy -November 01, 2023 at 06:30 am EDT

Merck & Co., Inc. announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck?s anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection…

Continue Reading Merck & Co., Inc. Announces Phase 3 Keynote-564 Trial Evaluating KEYTRUDA, Merck?s Anti-PD-1 Therapy -November 01, 2023 at 06:30 am EDT

Merck & Co., Inc. Announces Phase 3 Keynote-A39/Ev-302 Trial Met Dual Primary Endpoints of Overall Survival (Os) and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer -September 22, 2023 at 06:00 am EDT

Merck & Co., Inc. announced positive topline results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck?s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) versus chemotherapy (gemcitabine plus cisplatin or carboplatin) in patients with previously untreated…

Continue Reading Merck & Co., Inc. Announces Phase 3 Keynote-A39/Ev-302 Trial Met Dual Primary Endpoints of Overall Survival (Os) and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer -September 22, 2023 at 06:00 am EDT

AstraZeneca eagerness for CinCor revealed in larger first offer

AstraZeneca kicked off this year’s J.P.Morgan Healthcare Conference in style, announcing a $1.8 billion deal that gave it ownership of CinCor Pharma and its mid-phase hypertension drug baxdrostat. But while Fierce Biotech reported at the time that AstraZeneca was able to exploit CinCor’s deflated share price, that was only part…

Continue Reading AstraZeneca eagerness for CinCor revealed in larger first offer

Melanoma Recurrence Is Reduced By A Moderna, Merck & Co. Cancer Vaccine

Covid shot maker “Moderna” has brought shocking yet good news to the people that their collaboration with Merck had been successful. They initially signed an agreement in the year 2016. Furthermore, their collaboration has made an mRNA-4156/V940 cancer vaccine designed to stimulate an immune response to cancer-based on the DNA…

Continue Reading Melanoma Recurrence Is Reduced By A Moderna, Merck & Co. Cancer Vaccine

Global Nucleic Acid Labeling Market 2022 to 2028 Latest Innovations and Major Players are Merck & Co., Inc., PerkinElmer, Inc.

The global markets are being disrupted by the arrival of industry 4.0, which is accompanied by digitalization, automation, and artificial intelligence. Fundamental geopolitical shifts are changing global economic power centers. As a result, The Brainy Insights has launched a research study on the future of the global Nucleic Acid Labeling…

Continue Reading Global Nucleic Acid Labeling Market 2022 to 2028 Latest Innovations and Major Players are Merck & Co., Inc., PerkinElmer, Inc.